We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

Fund managers haven’t disclosed any holdings of PDSB yet.

PDSB Hedge Fund Activity: Q1 2026 in Review

41 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2026, worth a combined $3.05M — down 50% from $6.07M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PDSB and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.

The largest buyer was Geode Capital Management, adding an estimated $105K. The largest seller was Armistice Capital, cutting an estimated $2M.

  • 41 institutional investors held PDS Biotechnology (PDSB) as of Q1 2026, down from 44 in Q4 2025.
  • Funds reported $3.05M of PDS Biotechnology stock for Q1 2026, down 50% quarter-over-quarter.
  • 7 funds opened new PDS Biotechnology positions in Q1 2026 and 9 closed out, a net change of -2 holders.
  • The largest PDS Biotechnology buyer in Q1 2026 was Geode Capital Management, an estimated $105K added.
  • The largest PDS Biotechnology seller in Q1 2026 was Armistice Capital, an estimated $2M sold.

Based on aggregated 13F filings for Q1 2026.